Hayek Kallen Investment Management’s AstraZeneca AZN Stock Holding History

Hayek Kallen Investment Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,100	Closed	-$211K	–	65
2017 Q2	$211K	Buy	+3,100	New	+$202K	0.14%	59
2016 Q4	–	Sell	-3,300	Closed	-$217K	–	64
2016 Q3	$217K	Buy	+3,300	New	+$216K	0.15%	55
2016 Q1	–	Sell	-3,175	Closed	-$216K	–	58
2015 Q4	$216K	Hold	3,175	–	–	0.17%	52
2015 Q3	$202K	Buy	+3,175	New	+$209K	0.16%	54

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Hayek Kallen Investment Management's AZN Position: Q3 2017 in Review

Hayek Kallen Investment Management sold out of AstraZeneca (AZN) in Q3 2017, closing a stake of 3,100 shares — an estimated $211K sold.

Hayek Kallen Investment Management first reported a position in AZN in Q3 2015 and held it in 4 quarters. The position peaked at $217K in Q3 2016. 455 funds tracked by Wall St. Rank hold AZN as of Q3 2017.

Hayek Kallen Investment Management reported no remaining AstraZeneca position as of Q3 2017 after selling out during the quarter.
Hayek Kallen Investment Management sold 3,100 AstraZeneca shares in Q3 2017, an estimated $211K.
Hayek Kallen Investment Management first reported a position in AstraZeneca in Q3 2015 and held it in 4 quarters.
Hayek Kallen Investment Management's AstraZeneca position peaked at $217K in Q3 2016.
455 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2017.

Based on Hayek Kallen Investment Management's 13F filing for Q3 2017, filed 25 Oct 2017.